StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3025% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Cepheid (GeneXpert Molecular Diagnostics) by Quarter

Cepheid (GeneXpert Molecular Diagnostics) — Recall Events on openFDA

QuarterlyAnnualMonthly

Danaher Cepheid (GeneXpert Molecular Diagnostics): 0 in Q3 2026. That is the highest of the 35 quarters on record here.

Latest, Q3 2026
0
Period ended Sep 30, 2026
Change on a year earlier
–
0 in Q3 2025
History
35 quarters
Since Q1 2018
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)

Where the Q3 2026 figure comes from

Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Reported in U.S. FDA openFDA Device Recalls API.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCepheid (GeneXpert Molecular Diagnostics) — Recall Events on openFDAYear on yearSource
Q3 2026Sep 30, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2026Jun 30, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2026Mar 31, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2025Dec 31, 20250–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2025Sep 30, 20250–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2025Jun 30, 20250–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2025Mar 31, 20250–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2024Dec 31, 20240–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2024Sep 30, 20240–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2024Jun 30, 20240–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2024Mar 31, 20240–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2023Dec 31, 20230–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2023Sep 30, 20230–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2023Jun 30, 20230–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2023Mar 31, 20230–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2022Dec 31, 20220–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Cite this data

StockData. (2026). Danaher Cepheid (GeneXpert Molecular Diagnostics), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-recalls-cepheid

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.